The companies have forged a collaboration to support more personalized CT lung diagnosis with quantifiable clinical insights.

The LDA software received FDA approval and CE mark clearance for quantification and visualization of chronic obstructive pulmonary disease (COPD) components.

The collaboration allows customers to have their CT lung images automatically uploaded for processing with LDA, in addition to receiving both an augmented CT lung series with density overlays for detailed image interpretation.

The full workflow integration will allow streamlined processing to quantify and localize areas of low lung density and air trapping, offering physicians with secure clinical information to treat patients.

Imbio CEO Cynthia Maier said: "At Imbio, we are working to break down the barriers to broader use of clinically valuable quantitative imaging.

GE Healthcare software chief technology officer Evren Eryurek said: "This partnership with Imbio confirms our commitment to providing healthcare professionals with enhanced quantifiable clinical insights.

"By incorporating Imbio’s personalized lung analysis into GE Healthcare’s cloud¬-enabled workflow solutions, we are enriching the data that we can provide through the GE Health Cloud.

The LDA software is expected to available on the GE Health Cloud when it will be launched in the middle of this year.

Image: Imbio to incorporate Lung Density Analysis into GE Health Cloud platform. Photo: courtesy of Stuart Miles / FreeDigitalPhotos.net.